Breaking News

SCM Pharma Names BD Director

October 17, 2013

Bellamy brings 30 years of experience

Simon Bellamy has been appointed business development director at SCM Pharma. Mr. Bellamy will be responsible for new clinical trials business and small commercial opportunities for the company’s new $10 million facility in Newburn. He has 30 years of experience in the pharmaceutical industry. Most recently he held business development roles at Catalent Pharma Solutions and Piramal Healthcare.
Dianne Sharp, managing director at SCM Pharma, said, “Attracting Simon to our business is a major coup given his past experience in the contract manufacturing arena and he will no doubt add a huge amount of value to our exciting growth plans. We now have two of the finest sterile filling facilities in Europe catering for development, clinical trial projects and commercial supply, which gives Simon and his team a compelling service offering to take to the market.”
SCM Pharma specializes in the sterile production of products for clinical trials along with the supply of licensed drugs in niche markets. Its new facility completed a successful inspection from the MHRA this past summer.

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important